Navigation Links
New study suggests promising drug combinations for sleeping sickness

Results from a clinical trial evaluating new drug combinations for sleeping sickness, carried out by the international humanitarian medical aid agency Medecins Sans Frontieres (MSF), and its research arm, Epicentre, have now been published in the journal PLoS Clinical Trials.

African trypanosomiasis, or sleeping sickness affects many tens of thousands of people each year in sub-Saharan Africa and is a serious disease for which there are few treatment options. The most commonly used drug, Melarsoprol, is highly toxic. MSF and Epicentre jointly carried out a trial that started in 2001 in Uganda to evaluate the efficacy and safety of three drug combinations for this disease. The aim was to find out if any of these combinations would provide a viable treatment option for patients with second-stage sleeping sickness, where infection has reached the brain and prognosis is normally very poor. In the trial the drug combinations compared were melarsoprol-nifurtimox, melarsoprol-eflornithine, and nifurtimox-eflornithine. However, once 54 patients had been recruited (435 were planned), it was obvious that the death rate was much higher amongst individuals receiving one of the combinations, so the trial was stopped.

In the trial, the cure rate for nifurtimox-eflornithine was over twice that for melarsoprol-nifurtimox and substantially higher than that for melarsoprol-eflornithine. The rates of adverse events were also lower for patients treated with nifurtimox-eflornithine. These findings are encouraging and suggest that the nifurtimox-eflornithine combination has potential as a future therapy for second-stage African trypanosomiasis, and should be evaluated further in clinical trials.
'"/>

Source:Public Library of Science


Page: 1

Related biology news :

1. Bioartificial kidney under study at MCG
2. W.M. Keck Foundation funds study of friendly microbes
3. Yellowstone microbes fueled by hydrogen, according to U. of Colorado study
4. Genome-wide mouse study yields link to human leukemia
5. Clam embryo study shows pollutant mixture adversely affects nerve cell development
6. New imaging method gives early indication if brain cancer therapy is effective, U-M study shows
7. Same mutation aided evolution in many fish species, Stanford study finds
8. Sequencing of marine bacterium will help study of cell communication
9. Genetically modified rice in China benefits farmers health, study finds
10. A new study examines how shared pathogens affect host populations
11. NYU study reveals how brains immune system fights viral encephalitis

Post Your Comments:
(Date:11/26/2009)... survey carried out in eight European countries ha...fectious disease pandemic could have a significant...s writing in the open access journal BMC Infectio...on school days and weekends/holidays, finding that... Hens, from Hasselt and Antwerp University, Belgiu...
(Date:11/26/2009)...RSA (methicillin-resistant Staphylococcus Aureus ...ihilation as low-temperature plasma prototype devi... and unfailing bactericidal cocktails. , Two pro...ent disinfection of healthy skin (e.g. hands and f... can pose a lethal threat; and another to shoot ba...
(Date:11/25/2009)...thens, Ga. Bacteria don,t have easy lives. In add... bugs, they have natural enemies called bacterioph... every two days. , Still, bacteria and another ...overed in extreme environments such as deep-sea vo... because they have a built-in defense system that ...
Breaking Biology News(10 mins):School closure could reduce swine flu transmission by 21 percent 2Plasma produces KO cocktail for MRSA 2Plasma produces KO cocktail for MRSA 3Researchers discover biological basis of 'bacterial immune system' 2Researchers discover biological basis of 'bacterial immune system' 3Arena Pharmaceuticals to Present at the Piper Jaffray Fourth Annual Europe Conference 49329 1Arena Pharmaceuticals to Present at the Piper Jaffray Fourth Annual Europe Conference 49329 2Arena Pharmaceuticals to Present at the Piper Jaffray Fourth Annual Europe Conference 49329 3Jiangbo Pharmaceuticals to Attend the 44th China New Drugs Trade Fair in Tianjin 49327 1Jiangbo Pharmaceuticals to Attend the 44th China New Drugs Trade Fair in Tianjin 49327 2Jiangbo Pharmaceuticals to Attend the 44th China New Drugs Trade Fair in Tianjin 49327 3EUCODIS Bioscience Achieves Development Milestone in Second Collaboration With Lohmann Animal Health 4613 1EUCODIS Bioscience Achieves Development Milestone in Second Collaboration With Lohmann Animal Health 4613 2EUCODIS Bioscience Achieves Development Milestone in Second Collaboration With Lohmann Animal Health 4613 3
... 23, 2007, President Bush stated that, in order to... increase the supply of alternative fuels, by sett...on gallons of renewable and alternative fuels in 2...l refiner subsidy promised in the 2008 Farm Bill a... growers are putting energy needs ahead of environ...
...th breast cancer today are candidates for lumpecto...ast tissue. Results of a UC Davis study, however, ... the same breast are treated with a second lumpect...tment recommendations and cutting the number of ye...rised to find that so many women in our study alm...
...r undertaken of the upper U.S. Gulf Coast suggests...rs could flood large swaths of wetlands this centu...In terms of sea-level increases and river sediment... a time when bays will face conditions they last s...ears ago," said lead researcher John Anderson, the...
Other Biology News:Mandate for biofuels production requires science-based policy and global perspective 2Second lumpectomy for breast cancer reduces survival rates 2Bays on US Gulf Coast vulnerable to flooding 2
(Date:11/29/2009)... This release is available in German . , Th...as in modern physics. The most famous example is t...and neutrons. Now Prof. Bella Lake from Helmholtz-... of scientists report for the first time an experi...omenon observed in a condensed matter system. , ...
(Date:11/27/2009)..., , DURHAM, N.C., Nov. 27 /PRNewswire/..., will initiate water-soluble carbon nanotube-base... The water-soluble carbon nanotubes, which have fu...gation with cancer drugs, was developed in partner...e conjugated carbon nanotubes serves as a drug del...
(Date:11/27/2009)... A mechanised blue dye tes...n to packaging quality assurance one step closer f...contact leak testing machine developed by Sepha...en installed in several local and global pharma-co... address quality assurance and productivity improv...
(Date:11/25/2009)..., , DURHAM, N.C., Nov. 25 /PRNewswire/...led the first energy-efficient, single-treatment w...om carbon nanotubes to Andhra Pradesh, Minister of...her leaders in Hyderabad, India today. Initial tes...IT) Kanpur, confirmed that the majority of the dri...
Breaking Biology Technology:Spinons -- confined like quarks 2North Carolina Based Cromoz Inc. Launches Carbon Nanotechnology for Target Drug Delivery System in Cancer Treatment in Hyderabad, India 2Sepha's Blue Dye Test Alternative Brings ‘Complete Automation' To Pharma-Packaging Quality Assurance 2Sepha's Blue Dye Test Alternative Brings ‘Complete Automation' To Pharma-Packaging Quality Assurance 3North Carolina-based Cnanoz Unveils NanoPure(TM) to Government Leaders in Hyderabad, India 2
... Increased 5-Year Survival Data for Responding Pat...rporated (OTC Bulletin Board: GNTA) announced that...d and Drug Administration (FDA) for its,New Drug A...um) Injection,plus chemotherapy for patients with ...a (CLL). The submission is based on new informatio...
...June 6 DURECT Corporation,(Nasdaq: DRRX ) announ...at,three upcoming life sciences conferences in New...gy and Medical Technology Conference on Thursd...,s Pain Roundtable Conference, on Monday, June 23r... Healthcare Conference on Thursday, June 26th at ...
...une 6 InterMune, Inc.,(Nasdaq: ITMN ) today anno...,Chief Financial Officer of InterMune, will presen...Healthcare Conference in Dana Point, Calif. on,Jun...Hodgman will also,present at the Seventh Annual Ne...hnology Conference in New York on June 12, 2008 at...
Other Biology Technology:Genta Submits NDA Amendment to FDA for Genasense as Treatment of Chronic Lymphocytic Leukemia 2Genta Submits NDA Amendment to FDA for Genasense as Treatment of Chronic Lymphocytic Leukemia 3Genta Submits NDA Amendment to FDA for Genasense as Treatment of Chronic Lymphocytic Leukemia 4InterMune to Present at Goldman Sachs Healthcare and Needham & Co. Biotechnology and Medical Technology Conferences 2
Rat Anti-p19ARF Monoclonal Antibody, Unconjugated, Clone 5-C3-1 from Upstate
EDTA, tetrasodium salt from GE Healthcare, formerly Amersham Biosciences
Tracker Datamatrix RS-1* from Micronic BV
GeneAmplimer HIV-1 Control Reagents from Applied Biosystems
Biology Products: